Cellivery Therapeutics, Inc. Share Price
Equities
A268600
KR7268600004
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
6,680 KRW | -29.91% | -.--% | -.--% |
2023 | Cellivery Therapeutics, Inc.(KOSDAQ:A268600) dropped from S&P Global BMI Index | CI |
2021 | Cellivery Therapeutics, Inc. acquired Ajin Clean Co., Ltd. from SVAJ Holdings for KRW 14.2 billion. | CI |
Sales 2022 | 23.16B 17M 1.36B | Sales 2023 | 18.86B 13.85M 1.11B | Capitalization | 245B 180M 14.43B |
---|---|---|---|---|---|
Net income 2022 | -75.16B -55.17M -4.43B | Net income 2023 | -32.57B -23.91M -1.92B | EV / Sales 2022 | 20.8 x |
Net Debt 2022 | 48.13B 35.33M 2.83B | Net Debt 2023 | 44.76B 32.85M 2.64B | EV / Sales 2023 | 15.4 x |
P/E ratio 2022 |
-4.02
x | P/E ratio 2023 |
-7.51
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 85.67% |
1 day | -29.91% |
Managers | Title | Age | Since |
---|---|---|---|
Dae-Woong Cho
CEO | Chief Executive Officer | 56 | 13/03/14 |
Sun-Hong Kwon
BRD | Director/Board Member | 50 | 28/03/21 |
Byung-Hwa Lee
AUD | Comptroller/Controller/Auditor | 60 | 21/03/19 |
Members of the board | Title | Age | Since |
---|---|---|---|
Dae-Woong Cho
CEO | Chief Executive Officer | 56 | 13/03/14 |
Sun-Hong Kwon
BRD | Director/Board Member | 50 | 28/03/21 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 4 M€ | -4.41% | - |
1st Jan change | Capi. | |
---|---|---|
-.--% | 181M | |
-1.43% | 104B | |
+8.96% | 105B | |
+4.40% | 22.94B | |
-12.15% | 22.34B | |
-4.36% | 19.25B | |
-39.98% | 17.08B | |
-10.04% | 16.96B | |
+6.79% | 14.16B | |
+38.61% | 12.63B |
- Stock Market
- Equities
- A268600 Stock